Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

v3.10.0.1
Commitments and Contingencies (Details Textual)
 1 Months Ended 3 Months Ended 9 Months Ended
Jul. 09, 2015
USD ($)
Sep. 12, 2013
USD ($)
Feb. 21, 2017
USD ($)
Jun. 17, 2016
USD ($)
Feb. 15, 1999
USD ($)
Sep. 30, 2018
USD ($)
ft²
Sep. 30, 2018
USD ($)
ft²
Sep. 30, 2017
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Jul. 06, 2016
ft²
Commitments and Contingencies [Line Items]                        
Area of Land | ft²                       2,300
Payments to Acquire Intangible Assets             $ 250,000 $ 0        
Lease Expiration Period         12 years              
Payment of annual fee   $ 30,000                    
Contract with Customer, Liability, Revenue Recognized           $ 37,000 266,000          
Intangible Assets, Net (Excluding Goodwill)           $ 4,162,314 $ 4,162,314       $ 3,912,314  
License [Member]                        
Commitments and Contingencies [Line Items]                        
Cost of Goods and Services Sold   $ 50,000   $ 15,000 $ 12,500              
Subsequent Event [Member]                        
Commitments and Contingencies [Line Items]                        
Operating Leases, Future Minimum Payments Due                 $ 144,000 $ 43,000    
Minimum [Member] | License [Member]                        
Commitments and Contingencies [Line Items]                        
Cost of Goods and Services Sold       5,000                
Maximum [Member] | License [Member]                        
Commitments and Contingencies [Line Items]                        
Cost of Goods and Services Sold       $ 20,000                
New Valeant Agreement [Member]                        
Commitments and Contingencies [Line Items]                        
Revenues Recognition Milestone Method Description     the Company is eligible to receive milestone payments totaling up to approximately $99.0 million, upon and subject to the achievement of certain specified developmental and commercial progress of the EGP-437 Product for the New Field.                  
Proceeds From Upfront Payment     $ 4,000,000                  
Contract with Customer, Liability, Revenue Recognized     $ 99,000,000                  
Licensor [Member]                        
Commitments and Contingencies [Line Items]                        
Area of Land | ft²           4,516 4,516          
Valeant Pharmaceuticals International Inc [Member] | Licensing Agreements [Member]                        
Commitments and Contingencies [Line Items]                        
Payments to Acquire Intangible Assets $ 1,000,000                      
Proceeds from Sale of Intangible Assets $ 32,500,000                      
SentrX Animal Care Inc [Member]                        
Commitments and Contingencies [Line Items]                        
Intangible Assets, Net (Excluding Goodwill)           $ 250,000 $ 250,000          
Intangible Assets Expected Milestone Payable           $ 4,750,000 $ 4,750,000